November 30th, 2009

Reports the Pittsburgh Post-Gazette:

The fluid flowing into Alan Romatowski’s left arm for an hour could be a magical solution stopping his Alzheimer’s disease in its tracks or a drug that fails to live up to its promise or even a placebo without any chance of helping him.

Neither the 58-year-old former airline pilot nor anyone else in the room — his wife, his doctor or the clinical coordinator of UPMC’s Alzheimer Disease Research Center — knows what he’s getting as one of several thousand participants in a national study.

But Alan, one of the 10 percent of Alzheimer’s patients afflicted with the early-onset version of the disease before age 65, is hopeful. On a November morning, three years after showing dementia symptoms and two years after a devastating Alzheimer’s diagnosis, he has done well on a periodic test of his mental abilities.

On this day, he’s not forgetting words in midsentence. He doesn’t feel confused about anything. Alan insightfully answers questions posed by his neurologist, Dr. Oscar Lopez, about what might be happening to the Alzheimer’s-related amyloid plaque infiltrating his brain if he’s indeed receiving bapineuzumab instead of a phony clinical-trial substitute. The tongue-twister of a drug is among the most promising — though not yet proven — counters to the disease.

He’s like the old Alan Romatowski, who was so poised as a jetliner captain that he once coolly disarmed a hijacker when they were alone on a plane during the man’s standoff with police.

“On a day like today, I’m sure I’m getting the drug,” Alan says while briefly reclined in a hospital bed for a quarterly intravenous infusion. “I might be whistling in the graveyard, but I feel a lot more engaged.”

Read more at the Post-Gazette.


Leave a Comment